Search Results

You are looking at 21 - 30 of 43 items for :

  • "kidney disease" x
Clear All
Full access

Ning Ning, Jingsheng Yan, Xian-Jin Xie and David E. Gerber

Health National Institute of Diabetes and Digestive and Kidney Diseases Short-Term Institutional Research Training Grant (5 T35 DK 66141-10) (to N.N.). Biostatistical support was provided by the Biostatistics Shared Resource at the Harold C. Simmons

Full access

Vijaya Raj Bhatt, R. Gregory Bociek, Ji Yuan, Kai Fu, Timothy C. Greiner, Bhavana J. Dave, Sandeep K. Rajan and James O. Armitage

to have severe anemia and thrombocytopenia, and received platelet and packed red blood cell transfusions. A nasal endoscopy was performed and a bleeding vessel was cauterized. Previous medical history was significant for chronic kidney disease (CKD

Full access

Anita Pudusseri and Alex C. Spyropoulos

patients with renal impairment, because LMWH is contraindicated in patients with stage V chronic kidney disease (CKD) and necessitates a dose adjustment for patients with stage IV CKD (creatinine clearance, 15–30 mL/min). 13 TSOAC Use TSOACs are a

Full access

Kah Poh Loh, Maya Abdallah, Meng-Shiou Shieh, Mihaela S. Stefan, Penelope S. Pekow, Peter K. Lindenauer, Supriya G. Mohile, Dilip Babu and Tara Lagu

on quality of end-of-life care in cancer patients . Cancer 2014 ; 120 : 1743 – 1749 . 25. McAdoo SP Brown EA Chesser AM . Measuring the quality of end of life management in patients with advanced kidney disease: results from the pan

Full access

Arjun Gupta, Raseen Tariq, Ryan D. Frank, Gary W. Jean, Muhammad S. Beg, Darrell S. Pardi, David H. Johnson and Sahil Khanna

) 2016 ; 4 : 293 – 298 . 20. Keddis MT Khanna S Noheria A . Clostridium difficile infection in patients with chronic kidney disease . Mayo Clin Proc 2012 ; 87 : 1046 – 1053 . 21. Khanna S Gupta A Baddour LM Pardi DS

Full access

John A. Glaspy

-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease . Value Health 2008 ; 11 : 57 – 75 . 8. Leyland-Jones B . Breast cancer trial with erythropoietin terminated

Full access

Jennifer M. Hinkel, Edward C. Li and Stephen L. Sherman

: Clinical and Operational Impact Historical Perspective: Use of ESAs in Oncology, 1980s Through Early 2000s ESAs were originally studied in chronic kidney disease, with the first publications examining their use in a nephrology setting appearing in 1986. 3

Full access

Pamela Sue Becker, Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Shira Dinner, Ivana Gojo, Ashley Hicks, Avyakta Kallam, Wajih Zaheer Kidwai, Dwight D. Kloth, Eric H. Kraut, Daniel Landsburg, Gary H. Lyman, Ryan Miller, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Rachel Rosovsky, Vivek Roy, Hope S. Rugo, Sepideh Shayani, Sumithira Vasu, Martha Wadleigh, Kelly Westbrook, Peter Westervelt, Jennifer Burns, Jennifer Keller and Lenora A. Pluchino

approved the first epoetin alfa biosimilar, epoetin alfa-epbx, for anemia associated with administration of myelosuppressive chemotherapy, chronic kidney disease (CKD), or treatment of HIV, or to prevent the need for RBC transfusions in patients undergoing

Full access

Erin E. Hahn, Michael K. Gould, Corrine E. Munoz-Plaza, Janet S. Lee, Carla Parry and Ernest Shen

-specific treatment than those in class 3, which was characterized primarily by diabetes with microvascular complications, including kidney disease. Patients in class 3 were less likely to receive no treatment than those in class 2 across all disease Table 4

Full access

Linda S. Overholser and Carlin Callaway

management of hypertension and other conditions state that blood pressure goals may vary depending on patient age and presence of comorbid conditions, such as chronic kidney disease, diabetes, and CVD, but not specifically cancer, although do allow for